Last reviewed · How we verify
Marketed varicella vaccine_Lot 1 — Competitive Intelligence Brief
phase 3
Live attenuated vaccine
Varicella-zoster virus (VZV)
Immunology / Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
Marketed varicella vaccine_Lot 1 (Marketed varicella vaccine_Lot 1) — GlaxoSmithKline. The varicella vaccine stimulates the immune system to produce antibodies and cellular immunity against the varicella-zoster virus, preventing chickenpox infection.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Marketed varicella vaccine_Lot 1 TARGET | Marketed varicella vaccine_Lot 1 | GlaxoSmithKline | phase 3 | Live attenuated vaccine | Varicella-zoster virus (VZV) | |
| varicella-3 | varicella-3 | Beijing Center for Disease Control and Prevention | marketed | Live attenuated vaccine | Varicella-zoster virus | |
| Herpes Zoster | Herpes Zoster | Canadian Immunization Research Network | marketed | Live attenuated vaccine | Varicella-zoster virus (VZV) | |
| Herpes Zoster Vaccine, Live | Herpes Zoster Vaccine, Live | Changchun BCHT Biotechnology Co. | marketed | Live attenuated vaccine | ||
| Bacille Calmette-Guérin (BCG) | Bacille Calmette-Guérin (BCG) | TASK Applied Science | marketed | Live attenuated vaccine / Immunotherapy | Pattern recognition receptors (TLR2, TLR4, NOD2); non-specific immune activation | |
| Live Smallpox Vaccine | Live Smallpox Vaccine | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | marketed | Live attenuated vaccine | Vaccinia virus antigens (envelope and intracellular proteins) | |
| RotaTeq™ (V260) | RotaTeq™ (V260) | Merck Sharp & Dohme LLC | marketed | Live attenuated vaccine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Live attenuated vaccine class)
- GlaxoSmithKline · 19 drugs in this class
- Merck Sharp & Dohme LLC · 11 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
- PATH · 5 drugs in this class
- Sanofi · 5 drugs in this class
- Bandim Health Project · 5 drugs in this class
- Centers for Disease Control and Prevention · 3 drugs in this class
- International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
- Beijing Center for Disease Control and Prevention · 2 drugs in this class
- Aga Khan University · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Marketed varicella vaccine_Lot 1 CI watch — RSS
- Marketed varicella vaccine_Lot 1 CI watch — Atom
- Marketed varicella vaccine_Lot 1 CI watch — JSON
- Marketed varicella vaccine_Lot 1 alone — RSS
- Whole Live attenuated vaccine class — RSS
Cite this brief
Drug Landscape (2026). Marketed varicella vaccine_Lot 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/marketed-varicella-vaccine-lot-1. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab